Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing excess glucagon -to bring blood sugar back under control
February 20, 2026
Finally, the metabolic care landscape is expanding rapidly
Indeed, the tdc operon is strongly up-regulated in the inflamed gut of germ-free mice infected with AIEC and treated with DSS 112
In the Step 1 trial (note: funded by Novo-Nordisk) of 1,961 individuals, the average weight loss at 68 weeks was 14.9% at the maximum dose of 2.4 mg weekly, equating to 15.3 kg (33.6 lbs) lost compared to 2.6 kg (5.7 lbs) in the placebo group
